Patent classifications
C07C281/18
COMPOSITIONS, METHODS, AND SYSTEMS FOR THE SYNTHESIS AND USE OF IMAGING AGENTS
The present invention relates to systems, compositions, and methods for the synthesis and use of imaging agents, or precursors thereof. An imaging agent precursor may be converted to an imaging agent using the methods described herein. In some cases, the imaging agent is enriched in .sup.18F. In some cases, an imaging agent may be used to image an area of interest in a subject, including, but not limited to, the heart, cardiovascular system, cardiac vessels, brain, and other organs. In some embodiments, methods and compositions for assessing perfusion and innervation mismatch in a portion of a subject are provided.
INHIBITORS AND THEIR USES
The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R.sup.1a, R.sup.3a, R.sup.5a, X.sup.a and Y.sup.a are as defined herein.
##STR00001##
INHIBITORS AND THEIR USES
The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R.sup.1a, R.sup.3a, R.sup.5a, X.sup.a and Y.sup.a are as defined herein.
##STR00001##
METHODS FOR TREATING PROTOZOAN INFECTIONS
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.
METHODS FOR TREATING PROTOZOAN INFECTIONS
The invention provides compounds of Formula (I), and their use in methods for treating or preventing a protozoan infection in a subject using a compound of Formula (I). The invention also provides the use of a compound of Formula (I) in the manufacture of a medicament for the treatment of a protozoan infection in a subject. The invention further provides a medical device when used in a method of treating or preventing a protozoan infection in a subject and to a medical device comprising the composition of the invention.
Inhibitors of creatine transport and uses thereof
This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
Inhibitors of creatine transport and uses thereof
This invention relates to compounds that inhibit creatine transport and/or creatine kinase, pharmaceutical compositions including such compounds, and methods of utilizing such compounds and compositions for the treatment of cancer.
INHIBITORS AND THEIR USES
The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R.sup.1a, R.sup.3a, R.sup.5a, X.sup.a and Y.sup.a are as defined herein.
##STR00001##
INHIBITORS AND THEIR USES
The present invention relates to inhibitors of PPP1 R15A and PPP1 R15B and their use in therapy, particularly in the treatment of a disease state alleviated by the inhibition of PPP1 R15A and PPP1 R15B, for example a disorder associated with accumulation of misfolded proteins or proteostatsis disorder. Compounds of the invention include compounds having the formula IA or a pharmaceutically acceptable salt thereof, wherein R.sup.1a, R.sup.3a, R.sup.5a, X.sup.a and Y.sup.a are as defined herein.
##STR00001##
Guanidine compounds for removal of oxyanions from aqueous solutions and for carbon dioxide capture
Methods for removing oxyanions from water according to the following steps: (i) dissolving an oxyanion precipitating compound into the aqueous source to result in precipitation of an oxyanion salt of the oxyanion precipitating compound; and (ii) removing the oxyanion salt from the water containing the oxyanion to result in water substantially reduced in concentration of the oxyanion; wherein the oxyanion precipitating compound has the following composition: ##STR00001##
wherein A is a ring-containing moiety and X.sup.m is an anionic species with a magnitude of charge m. The invention employs bis-iminoguanidinium compounds according to Formula (1a) as well as neutral precursor compounds according to Formula (1), which can be used for removing undesirable species from aqueous solutions or air, such as removal of sulfate from water and carbon dioxide from air.